Gender-Affirming Hormone Therapy

What Is Gender-Affirming Hormone Therapy?

Gender-affirming hormone therapy (GAHT), also commonly called gender-affirming HRT, is a medically supervised treatment that aligns a person's endogenous hormone profile with their gender identity. For transgender, nonbinary, and gender-diverse (TGD) patients, HRT is a cornerstone of medical transition and is recognized as medically necessary, evidence-based care by virtually every major medical organization in the United States and internationally, including the American Medical Association (AMA), American Psychological Association (APA), American Academy of Pediatrics (AAP), Endocrine Society, and the World Professional Association for Transgender Health (WPATH).

There are three broad treatment pathways within gender-affirming HRT. Feminizing hormone therapy uses estradiol combined with an anti-androgen (and sometimes progesterone) to produce physical changes associated with estrogen-dominant puberty -- breast development, softer skin, fat redistribution, reduced body hair, and decreased erectile function. It is prescribed for trans women, transfeminine people, and AMAB (assigned male at birth) nonbinary individuals. Masculinizing hormone therapy uses testosterone alone to produce changes associated with androgen-dominant puberty -- voice deepening, facial and body hair growth, increased muscle mass, clitoral enlargement, and cessation of menses. It is prescribed for trans men, transmasculine people, and AFAB (assigned female at birth) nonbinary individuals. Non-binary or low-dose approaches use fractional or selective protocols tailored to goals that do not fit a binary transition model.

The goals of gender-affirming HRT extend beyond physical changes. Peer-reviewed research consistently demonstrates that HRT significantly reduces gender dysphoria, depression, and suicidality, while improving quality of life, body image, social functioning, and overall psychological well-being. A 2022 JAMA Network Open study of more than 21,000 TGD adults found that access to gender-affirming hormone therapy was associated with a 73% reduction in past-month suicidal ideation compared to those who wanted but could not access HRT.

The current clinical standard is the WPATH Standards of Care version 8 (SOC 8), published in September 2022. SOC 8 replaced the previous version's rigid age, duration, and psychiatric-evaluation requirements with a patient-centered, individualized assessment model that emphasizes informed consent, shared decision-making, and the elimination of unnecessary gatekeeping. Together with the Endocrine Society Clinical Practice Guideline and the UCSF Gender Affirming Health Program (GAHP) protocols, these documents form the backbone of modern TGD care.

WPATH Standards of Care Version 8 (SOC 8) Overview

The World Professional Association for Transgender Health published the 8th edition of its Standards of Care in September 2022 after more than five years of multidisciplinary review. SOC 8 is organized into 18 chapters covering global applicability, terminology, assessment, adolescents, adult care, hormone therapy, surgery, voice and communication, primary care, reproductive health, mental health, sexual health, education, eunuch-identified people, nonbinary people, intersex considerations, and institutional environments. It remains the single most influential clinical reference document in gender-affirming medicine.

The most important change from SOC 7 (2011) to SOC 8 is the removal of previously rigid prerequisites. SOC 7 required a minimum of 12 months of "living in the identified gender" before surgery, required two independent mental health letters for many procedures, and implied fixed durations of hormone therapy. SOC 8 removes these fixed thresholds. Instead, it establishes a principles-based framework: care should be individualized, grounded in a thorough assessment of the patient's needs and goals, and delivered without unnecessary barriers. For most gender-affirming surgeries, SOC 8 now requires only one letter of support from a qualified health professional, down from the previous two.

For hormone therapy initiation in adults, SOC 8 establishes the following minimum criteria: (1) persistent gender incongruence, well-documented; (2) capacity to provide informed consent; (3) that other possible causes of apparent gender incongruence have been addressed; and (4) that physical and mental health conditions that could significantly affect treatment outcomes have been assessed and managed. Notably, SOC 8 does not require a fixed number of therapy sessions, a psychiatric diagnosis, or a "real-life experience" period before starting HRT.

Care for adolescents is addressed in a separate chapter with additional considerations, including multidisciplinary assessment, family involvement, and recognition that pubertal suppression with GnRH agonists is generally reversible and provides time for unhurried decision-making. SOC 8 explicitly supports individualized care for nonbinary patients and acknowledges that treatment goals may not align with full feminization or full masculinization. The document also addresses eunuch-identified individuals for the first time, reflecting the diversity of goals that exist within the TGD community.

Feminizing Hormone Therapy

Feminizing HRT is prescribed for trans women, transfeminine, and AMAB nonbinary people who wish to develop secondary sex characteristics associated with estrogen-dominant puberty. It consists of three potential components: estrogen (estradiol), an anti-androgen to suppress testosterone, and optionally progesterone. The typical goal is to bring estradiol into the mid-range of cisgender premenopausal female values (100-200 pg/mL) and testosterone below 50 ng/dL.

Estrogen (Estradiol) Options

Only 17-beta estradiol (often written simply as estradiol) is used in modern gender-affirming care. Ethinyl estradiol and conjugated equine estrogens (Premarin) are no longer recommended due to significantly higher rates of venous thromboembolism (VTE). All major routes of administration produce effective feminization when dosed appropriately.

• Estradiol transdermal patches -- 0.1-0.4 mg (100-400 mcg) applied twice weekly. Delivers steady serum levels and carries the lowest documented VTE risk of any delivery route, making patches the preferred first-line option for patients over 40, smokers, or those with a personal/family history of thromboembolism.
• Estradiol oral / sublingual tablets -- 2-8 mg daily. Sublingual administration (dissolved under the tongue) is often preferred because it partially bypasses hepatic first-pass metabolism, achieves higher serum estradiol peaks, and reduces liver strain compared to swallowed oral dosing.
• Estradiol valerate intramuscular injection -- 5-20 mg every 1-2 weeks. Produces characteristic peak-trough kinetics similar to testosterone injections.
• Estradiol cypionate intramuscular injection -- 2-10 mg weekly. Shorter ester than valerate; slightly flatter serum curves and popular in U.S. gender-affirming clinics.
• Transdermal estradiol gel -- multiple pumps applied daily to upper arms or thighs. Requires larger doses than patches to achieve feminizing levels, but offers dose flexibility and avoids injections.

Target estradiol: 100-200 pg/mL (mid-range of cisgender premenopausal female values). Levels above 400 pg/mL are generally avoided because they do not accelerate feminization and may increase VTE risk.

Anti-Androgen Options

In the absence of orchiectomy, most patients require an anti-androgen alongside estradiol to achieve adequate testosterone suppression. Estradiol alone, even at higher doses, is often insufficient to fully suppress endogenous testosterone.

• Spironolactone -- 100-300 mg daily (maximum 400 mg). The most commonly prescribed anti-androgen in the United States. Spironolactone is an aldosterone antagonist that also blocks androgen receptors and suppresses testosterone synthesis. Common side effects include increased urination, hyperkalemia, dizziness, and occasional breast tenderness. Requires periodic monitoring of serum potassium and kidney function.
• Cyproterone acetate -- 25-50 mg daily. Not available in the United States but widely used in Europe, Canada, and Australia. More potent testosterone suppression than spironolactone; risks include hepatotoxicity, meningioma (at higher cumulative doses), and depression, leading most European guidelines to recommend lower doses than historically used.
• GnRH agonists (leuprolide/Lupron, goserelin/Zoladex) -- monthly or quarterly depot injections. The most effective testosterone suppression available; approaches post-orchiectomy levels. Typically reserved for adolescents (pubertal suppression), patients who cannot tolerate other anti-androgens, or those with persistently elevated testosterone on spironolactone. Cost and insurance barriers are significant.
• Bicalutamide -- 12.5-25 mg daily. WPATH SOC 8 explicitly recommends against routine use of bicalutamide for feminization due to a lack of long-term safety data and reports of severe, occasionally fatal liver toxicity. Some providers still use it in limited circumstances for patients with persistent androgenization refractory to other agents, with close liver-enzyme monitoring.
• 5-alpha reductase inhibitors (finasteride 1-5 mg, dutasteride 0.5 mg) -- prevent the conversion of testosterone to dihydrotestosterone (DHT). Used as add-on therapy for scalp hair preservation and reduction of body hair. Not a substitute for primary anti-androgens.

Target testosterone: below 50 ng/dL (cisgender adult female range is roughly 30-100 ng/dL).

Progesterone

The role of progesterone in feminizing HRT remains debated. Micronized progesterone (Prometrium) 100-200 mg daily, taken orally or vaginally, is the form used in gender-affirming contexts. Potential benefits proposed by advocates and some clinicians include enhanced breast development (particularly rounder, fuller contours), improved mood, better sleep, and increased libido. However, rigorous evidence for these benefits remains limited, and theoretical concerns about breast cancer and cardiovascular risk exist based on extrapolation from menopausal HRT literature. Many gender clinics offer progesterone upon patient request, typically after 12 months of estrogen therapy once initial breast budding has occurred.

Timeline of Feminizing Changes

Masculinizing Hormone Therapy

Masculinizing HRT is prescribed for trans men, transmasculine, and AFAB nonbinary people who wish to develop secondary sex characteristics associated with androgen-dominant puberty. Unlike feminizing HRT, it requires only a single component: testosterone. The goal is to raise serum testosterone into the cisgender adult male range (300-1000 ng/dL), with many clinicians specifically targeting 400-700 ng/dL as the physiologic sweet spot.

Testosterone Options

• Testosterone cypionate IM -- 50-100 mg weekly or 100-200 mg every two weeks. The most commonly prescribed formulation in the United States. Half-life of approximately 8 days.
• Testosterone enanthate IM -- equivalent dosing to cypionate. Slightly shorter half-life (5-7 days); more common in Europe.
• Subcutaneous testosterone injection -- same dosing as IM but injected into abdominal or thigh subcutaneous tissue with a shorter needle. Growing rapidly in popularity because it is less painful, easier to self-administer, and produces comparable serum levels to IM injection.
• Testosterone gel (AndroGel, Testim, Fortesta) -- 25-100 mg applied daily to clean, dry skin of the shoulders or upper arms. Slower initial results, but steadier serum levels. Carries a transference risk to partners, children, and pets.
• Testopel pellets -- 6-12 subcutaneous pellets implanted every 3-6 months in a brief in-office procedure. Provides the steadiest serum levels available; less flexibility for dose adjustment.

Starting Dose and Titration

Many gender-affirming clinicians start patients at approximately half of the target dose and titrate upward over 3-6 months. A typical protocol begins with 50 mg testosterone cypionate weekly for the first 3-6 months, then increases to 100 mg weekly based on symptoms, serum levels, and goals. A slower start reduces the intensity of emotional adjustment, lowers the risk of erythrocytosis, and allows patients to choose their own pace of physical change. For nonbinary patients pursuing partial masculinization, the starting dose may become the maintenance dose.

Target testosterone: 300-1000 ng/dL (cisgender male range). Many clinicians specifically target 400-700 ng/dL for optimal symptom response with minimal side effects. Both peak (24-48 hours post-injection) and trough (just before next dose) levels should be checked when fine-tuning a protocol, especially for injectable testosterone.

Timeline of Masculinizing Changes

Non-Binary and Low-Dose Approaches

WPATH SOC 8 explicitly supports individualized, non-binary treatment goals and acknowledges that many TGD people do not want the full suite of changes produced by standard feminizing or masculinizing protocols. Low-dose, selective, or time-limited regimens allow patients to pursue specific desired effects while avoiding or delaying others. These approaches require careful counseling about which changes are reversible, which are permanent, and what the realistic timeline looks like at sub-standard doses.

Options for AMAB Non-Binary People

• Low-dose estradiol (25-50% of typical feminizing doses) to produce gradual softening of skin, mild fat redistribution, and reduced libido without rapid breast development.
• Spironolactone alone as a partial feminization strategy. Produces testosterone suppression, softer skin, reduced body hair, and decreased libido without the effects of estrogen.
• Time-limited estradiol with a planned stop point once desired changes are achieved. Some reversible effects will regress; breast tissue is permanent.
• Selective goal protocols -- for example, brief estradiol courses aimed at fat redistribution and skin softening while minimizing breast growth.

Options for AFAB Non-Binary People

• Microdosing testosterone at 25-50% of standard dose (e.g., 20-25 mg cypionate weekly instead of 50-100 mg). Produces slower, more gradual changes and gives patients more control over endpoints.
• Targeted effects such as clitoral growth, subtle voice deepening, and modest body composition changes without full masculinization.
• Delayed or absent amenorrhea -- at microdoses, menses may continue, which is desirable for some patients and problematic for others.
• Short courses of standard-dose testosterone (6-12 months) followed by discontinuation, understanding that voice deepening and hair growth achieved during this window will be permanent.

Reversibility is the central counseling topic. Before starting any low-dose or time-limited protocol, patients should understand which specific changes are temporary and which cannot be undone, so they can make fully informed decisions about their personal trajectory.

Monitoring and Laboratory Work

Ongoing laboratory monitoring is essential for safe and effective gender-affirming HRT. Labs confirm that hormone levels are in the desired range, detect side effects early, and guide dose adjustments. The UCSF Gender Affirming Health Program guidelines, WPATH SOC 8, and the Endocrine Society all recommend a similar schedule: baseline, 3 months, 6 months, and then annually once stable.

Feminizing HRT Lab Schedule

• Baseline (before starting): Estradiol, total and free testosterone, prolactin, LH, FSH, comprehensive metabolic panel (CMP), complete blood count (CBC), lipid panel, hemoglobin A1c, and age-appropriate baseline screenings.
• 3 months: Estradiol, total testosterone, and serum potassium if on spironolactone.
• 6 months: Estradiol, total testosterone, potassium, prolactin.
• Annually (once stable): Full panel plus DEXA bone density scan as indicated, and routine age-appropriate cancer and cardiovascular screening.

Masculinizing HRT Lab Schedule

• Baseline: Total and free testosterone, estradiol, CBC (with attention to hematocrit), CMP (liver and kidney function), lipid panel, and hemoglobin A1c.
• 3 months: Testosterone (both peak and trough if clinically helpful), estradiol, hematocrit.
• 6 months: Full hormone and safety panel.
• Annually: Full panel plus cervical cancer screening (if cervix remains), chest/breast screening (if breast tissue remains), and routine preventive care.

Target Ranges at a Glance

Key safety markers: On feminizing HRT, serum potassium should stay below 5.5 mEq/L for patients on spironolactone, and prolactin should remain within normal limits (sustained elevations may indicate a prolactinoma). On masculinizing HRT, hematocrit below 54% is the single most important cardiovascular safety parameter because elevated hematocrit increases blood viscosity and thromboembolism risk.

Side Effects and Risk Management

Gender-affirming HRT is well-tolerated by the large majority of patients, and most side effects are dose-dependent, predictable, and manageable through protocol adjustment. Understanding the specific risks of each pathway allows for proactive monitoring and intervention.

Feminizing HRT Risks

• Venous thromboembolism (VTE) -- deep vein thrombosis and pulmonary embolism. Risk is highest with oral conjugated estrogens and ethinyl estradiol (no longer recommended), moderate with oral estradiol, and lowest with transdermal patches and injections. Risk factors include smoking, age over 40, obesity, and personal/family history.
• Hypertension -- spironolactone paradoxically can raise blood pressure in some patients despite its diuretic action.
• Hyperkalemia -- elevated potassium, particularly when spironolactone is combined with potassium supplements, ACE inhibitors, or high-potassium diets.
• Hyperprolactinemia -- elevated prolactin. Rare, but persistent elevation warrants imaging to rule out prolactinoma.
• Weight gain and body composition changes.
• Mood changes during the initial adjustment period.
• Breast cancer risk -- epidemiologic data suggest a risk similar to cisgender women, which is higher than cisgender men but low in absolute terms.
• Bone density loss if estradiol drops below the target range, especially after orchiectomy.

Masculinizing HRT Risks

• Polycythemia / erythrocytosis -- the most common side effect. Managed with dose reduction, more frequent smaller injections, or therapeutic phlebotomy.
• Acne and oily skin -- usually worst during the first 1-2 years; managed with standard dermatologic care.
• Male-pattern baldness in genetically predisposed patients. Finasteride or minoxidil may help preserve scalp hair.
• Sleep apnea -- rare, but testosterone can worsen pre-existing obstructive sleep apnea.
• Mood changes during dose adjustments; most patients report overall mood improvement, but irritability can occur in the early weeks.
• Lipid shifts -- modest decreases in HDL and small increases in LDL in some patients.
• Vaginal atrophy -- managed with topical estrogen cream as needed without affecting systemic masculinization.
• Pelvic cramping or spotting during the first few months of therapy.

Fertility Impact

Both pathways substantially affect fertility. Feminizing HRT reduces spermatogenesis over months and may eliminate it entirely after sustained therapy. Recovery after discontinuation is possible but not guaranteed. Sperm banking before starting HRT is the most reliable way to preserve fertility. Masculinizing HRT reduces fertility but does not reliably prevent pregnancy; patients with a uterus who could become pregnant should use appropriate contraception if pregnancy would be unwanted. Egg or embryo freezing before testosterone is an option for those wishing to preserve fertility.

The Informed Consent Model

The informed consent model is an alternative to the traditional psychiatric gatekeeping approach to gender-affirming care. Under informed consent, patients are presumed to be the experts on their own identities and are treated as capable adults who can weigh the benefits and risks of HRT with their clinician. Rather than requiring letters from mental health professionals, the patient and provider engage in a detailed discussion covering expected physical and emotional effects, realistic timelines, permanent versus reversible changes, fertility implications, and known medical risks. The patient then signs an informed consent document indicating that they understand and accept these elements.

Informed consent is fully compatible with WPATH SOC 8 and is endorsed as a valid model of care by the Endocrine Society, the UCSF Gender Affirming Health Program, Planned Parenthood, and hundreds of independent gender clinics across the U.S. It still requires a full medical evaluation, baseline laboratory work, screening for conditions that could affect treatment safety, and ongoing follow-up -- but it removes the mental health letter requirement that historically delayed HRT access by months or years.

Hormone Pharma offers gender-affirming HRT through an informed consent pathway. No mental health letter is required to begin HRT. A letter of support is only required for certain gender-affirming surgeries, per SOC 8. Most patients can go from initial assessment to their first prescription within 1-2 weeks of their first appointment, assuming their baseline labs are in order.

Cost Breakdown

Monthly costs for gender-affirming HRT vary widely depending on delivery method, insurance coverage, and pharmacy. The table below reflects typical 2026 U.S. pricing. Compounded formulations from specialty pharmacies are often less expensive than brand-name products for equivalent efficacy.

Insurance coverage in 2026: Most commercial insurance plans cover medically necessary gender-affirming HRT. The Affordable Care Act (ACA) Section 1557 prohibits discrimination on the basis of gender identity in federally funded health programs and insurance exchanges. Medicare covers medically necessary HRT for TGD beneficiaries. Medicaid coverage varies by state, though the number of states offering explicit coverage has expanded substantially over the past several years.

Gender-Affirming HRT Products

All medications below are FDA-approved, dispensed from licensed U.S. pharmacies, and require a valid prescription from a licensed physician. Start with a confidential online assessment to determine which products are right for your goals.